This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
IGCS 2022
Presentations
Cervical Cancer | Abstract #406
Assessing Geographic Variation in Rates of Recurrent or Metastatic Cervical Cancer (Based on Commencement of Systemic Therapy) Among Medicaid Enrollees
Tisotumab Vedotin | Cervical Cancer | Abstract #192
Potential Mechanism for Ocular Adverse Events Observed with Tisotumab Vedotin
Tisotumab Vedotin | Cervical Cancer | Abstract #1457
Trial in Progress Update on ENGOT-cx8/GOG-3024/innovaTV 205: Addition of a New Cohort With First-Line Tisotumab Vedotin + Pembrolizumab + Carboplatin ± Bevacizumab in Recurrent/Metastatic Cervical Cancer